Feasibility, Fidelity, and Effectiveness of Administering Long-Acting Cabotegravir + Rilpivirine in Infusion Centers in the United States: Findings From the Phase 4 GLACIER Implementation Study
Journal of the International Association of Providers of AIDS Care (JIAPAC) · 2026-01 · 25
DOI: 10.1177/23259582261439585 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Journal of the International Association of Providers of AIDS Care (JIAPAC), online erschienen am 12.05.2026. Verfasst von Cassidy A Gutner und 16 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, Durham, NC, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, Pyridones, Rilpivirine. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ViiV Healthcare.
Abstract (Originalsprache)
Background
GLACIER (Giving Long-Acting Cabotegravir plus rilpivirine [CAB + RPV LA] in an Infusion Center [IC]) is a Phase 4 implementation study evaluating the perspective of people living with HIV-1 (participants) and IC staff on CAB + RPV LA delivery at ICs over 8 months.
Methods
Participants and IC staff completed quantitative questionnaires on feasibility (Feasibility of Intervention Measure [FIM]) and acceptability (Acceptability of Intervention Measure [AIM]) at Month (M) 1, M3, and M8; both scales comprised four items, rated on a 1 to 5 Likert scale (1 “completely disagree” to 5 “completely agree”). Semistructured qualitative interviews and clinical outcomes data were also collected.
Results
Among 44 enrolled participants (mean age 46 years), 51% were CAB + RPV LA-naive; 113 IC staff were enrolled. At M1, mean FIM scores (standard deviation [SD]) indicated that both groups found IC administration highly feasible (participants: 4.44 [0.80]; IC staff: 3.71 [0.97]), with scores remaining high at M3 (participants: 4.53 [0.69]; IC staff: 3.86 [0.72]) through to M8 (participants: 4.41 [0.80]; IC staff: 4.00 [0.81]). Similar findings were observed for mean AIM scores (SD), indicating high acceptance at M1 (participants: 4.51 [0.66]; IC staff: 3.65 [0.89]) to M3 (participants: 4.60 [0.67]; IC staff: 3.60 [0.97]) through to M8 (participants: 4.51 [0.55]; IC staff: 3.96 [0.84]). Qualitative data supported these observations. Of 194 injections, 96.4% were within the treatment window; virological suppression was maintained with no confirmed virological failures or adverse event-related discontinuations.
Conclusions
CAB + RPV LA administration at ICs was feasible, acceptable, well-tolerated, and effective. ClinicalTrials.gov number NCT04982445 ( https://clinicaltrials.gov/study/NCT04982445 )
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ViiV Healthcare, Durham, NC, USA.
- GSK, Bangalore, Karnataka, India.
- GSK, Collegeville, PA, USA.
- ViiV Healthcare, Upper Providence, PA, USA.
- Evidera, a business unit of Thermo Fisher Scientific, Wilmington, NC, USA.
- Infusion Associates, Grand Rapids, MI, USA.
Förderung
- ViiV Healthcare
Zitieren
APA
Gutner, C. A., Harrington, C., Bontempo, G., Pazhamalai, S., Kumar, A., Rimler, K., Davis, K., Williams, W., Merrill, D., Petty, L., Garris, C., Sarkar, S., Daniele, P., Gaglio, B., May, K., Aboud, M., & Czarnogorski, M. (2026). Feasibility, Fidelity, and Effectiveness of Administering Long-Acting Cabotegravir + Rilpivirine in Infusion Centers in the United States: Findings From the Phase 4 GLACIER Implementation Study. Journal of the International Association of Providers of AIDS Care (JIAPAC), 25. https://doi.org/10.1177/23259582261439585
Vancouver
Gutner CA, Harrington C, Bontempo G, Pazhamalai S, Kumar A, Rimler K, et al. Feasibility, Fidelity, and Effectiveness of Administering Long-Acting Cabotegravir + Rilpivirine in Infusion Centers in the United States: Findings From the Phase 4 GLACIER Implementation Study. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2026;25. doi:10.1177/23259582261439585
BibTeX
@article{Gutner2026,
author = {Gutner, Cassidy A and Harrington, Conn and Bontempo, Gilda and Pazhamalai, Sivakumar and Kumar, Abhishek and Rimler, Kelly and Davis, Karen and Williams, Will and Merrill, Deanna and Petty, Lisa and Garris, Cindy and Sarkar, Supriya and Daniele, Patrick and Gaglio, Bridget and May, Katie and Aboud, Michael and Czarnogorski, Maggie},
title = {Feasibility, Fidelity, and Effectiveness of Administering Long-Acting Cabotegravir + Rilpivirine in Infusion Centers in the United States: Findings From the Phase 4 GLACIER Implementation Study},
journal = {Journal of the International Association of Providers of AIDS Care (JIAPAC)},
year = {2026},
volume = {25},
doi = {10.1177/23259582261439585}
}
EUVIMED